On 11 August 2022, the Food and Drug Administration (FDA) gave accelerated approval to trastuzumab deruxtecan (T-DXd) for adults with previously treated, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring activating mutations in the gene encoding human epidermal growth factor receptor 2 (HER2), based on an interim efficacy analysis of DESTINY-Lung02 phase II clinical trial [1]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.